ORIC-944, a selective PRC2 inhibitor targeting the EED subunit, is showing promise in a Phase 1b trial for metastatic castration-resistant prostate cancer (mCRPC).
Early data from its combination with apalutamide revealed significant reductions in PSA levels: three of six patients achieved PSA50 responses (≥50% reduction), with two showing PSA90 responses (≥90% reduction), sustained for at least 12 weeks and one ongoing at 38 weeks.
The therapy was well-tolerated, with only mild-to-moderate side effects and no dose-limiting toxicities. Progress with the darolutamide combination cohort further supports its potential. Plans for registrational trials are anticipated in early 2026.
A new study reveals how a clotting protein and blood platelets can promote cancer progression and suppress immune responses to cancer